Eva Harris PhD

Professor, Division of Infectious Diseases and Vaccinology
Director, Center for Global Public Health
  • PH292/3: Immune Evasion in Host-Pathogen Interactions
  • PH260F: Infectious Disease Research in Developing Countries (Spring)
  • PH265: Molecular Parasitology (Fall)
Research Interests: 
  • Molecular virology, pathogenesis, immunology, epidemiology, and control of dengue
  • Epidemiology of influenza in tropical countries
  • Scientific capacity building in developing countries
Research Description: 

Dr. Harris has developed a multidisciplinary approach to study the molecular virology, pathogenesis, immunology, epidemiology, clinical aspects, and control of dengue. Her work investigates viral and host factors that modulate disease severity and immune correlates of protection and pathogenesis, using in vitro approaches, animal models, and research involving human populations. In vitro studies have focused on functional characterization of antibodies and B cell memory response, virus-host interactions and viral pathogenesis, viral fitness and evolution, and the mechanism of DENV translation and replication. The mouse models developed by her group recapitulate many aspects of human dengue disease and immune response, including antibody-dependent enhancement of DENV infections, and are being used to identify antibody determinants of protection, enhancement, and therapeutic efficacy. Her international work focuses on laboratory-based and epidemiological studies of dengue, chikungunya and influenza in endemic Latin American countries, particularly in Nicaragua. Long-term collaborations include clinical and biological studies of severe dengue through a 17-year pediatric hospital-based study, a 12-year pediatric cohort study of dengue, chikungunya and influenza transmission in Managua, and a recently concluded cluster randomized controlled trial of evidence-based community-derived interventions to prevent and control dengue.

Selected Publications: 

Beatty, P.R., Puerta Guardo, H., Killingbeck, S., Glasner, D., Hopkins, K., and Harris, E. (2015) Dengue virus non-structural protein 1 (NS1) triggers vascular leak that can be inhibited by anti-NS1 antibodies. Sci Transl Med. In press.

Andersson, N., Nava-Aguilera, E., Arostegui, J., Morales-Perez, A., Suazo-Laguna, H., Legorreta-Soberanis, J., Hernandez-Alvarez, C., Fernandez-Salas, I., Balmaseda, A., Cortés-Guzmán, A.J., Coloma, J., Ledogar, R.J., and Harris, E. (2015) Camino Verde (Green Way) to Dengue Prevention: a pragmatic cluster-randomised controlled trial of evidence-based community mobilisation in Nicaragua and Mexico. BMJ. 351:h3267.

Fibriansah, G., Ibarra, K.D., Ng, T.-S., Smith, S.A., Tan, J.L., Lim, X.-N., Kostyuchenko, V.A., Wang, J., de Silva, A.M., Harris, E., Crowe, J.E, Jr., and Lok, S.-M. (2015) CryoEM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science. 349:88-91.

Fong, H. and Harris, E. (2015) Technology, innovation, and health equity. Bull World Health Organ. 93:438-438A.

Schmid, M.A. and Harris, E. (2014) Monocyte recruitment to the dermis and differentiation to dendritic cells increases the targets for dengue virus replication. PLoS Pathog. 10(12):e1004541.

Quiner, C.A., Parameswaran, P., Ciota, A.T., Ehrbar, D.J., Dodson, B.L., Schlesinger, S., Kramer , L.D., and Harris, E. (2014) Increased replicative fitness of a dengue virus 2 clade in native mosquitoes: Potential contribution to a clade replacement event in Nicaragua. J. Virol. 88(22):13125-34.

Montoya, M.,* Gresh, L.,* Mercado, J.C., Williams, K.L., Vargas, M.J., Gutierrez, G., Kuan, G., Gordon, A., Balmaseda, A., Harris, E. (2013) Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis. 7(8):e2357.

Parameswaran, P., Liu, Y., Roskin, K., Jackson, K., Dixit, V.P., Lee, J.-Y., Artiles, K., Zompi, S., Vargas, M.J., Simen, B.B., Hanczaruk, B., McGowan, K.R., Tariq, M.A., Pourmand, N., Koller, D., Balmaseda, A., Boyd, S.D.,* Harris, E.,* Fire, A.Z.* (2013) Convergent antibody signatures in human dengue. Cell Host Microbe. 13:691-700. *Co-corresponding authors.

Williams, K.L., Sukupolvi-Petty, S., Beltramello, M., Johnson, S., Sallusto, F., Lanzavecchia, A., Diamond, M.S., Harris, E. (2013) Therapeutic efficacy against lethal dengue virus infection of antibodies lacking Fcγ receptor binding is due to neutralizing potency and blocking of enhancing antibodies. PLoS Pathog. 9:e1003157.

Zompi Z, Montoya M, Pohl M, Balmaseda A, Harris E. (2012) Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl Trop Dis. 6: e1568.

OhAinle M, Balmaseda A, Macalalad AR, Tellez Y, Zody MC, Saborío S, NuñezA, Lennon NJ, Birren BW, Gordon A, Henn MR, Harris E. (2011) Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Science Transl Med. 3:114ra128.

Other interests: 
  • President, Sustainable Sciences Institute
  • Director, Center for Global Public Health
  • Infectious Diseases and Immunity Graduate Group
  • Microbial Biology Graduate Group
Profile Updated: April 6, 2016